An interventional study of Intrathecal Morphine and Trocar-Site Bupivacaine Infiltration in Postoperative Pain Management, Laparoscopic Hysterectomy and Postoperative Recovery, sponsored by Ataturk University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Ataturk University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies testing morphine in Pain, Postoperative — 18 open to participants now, 21 under way, 1 of them phase 3. Morphine · Pain, Postoperative.
Among the 97 studies testing morphine in Pain, Postoperative, this one is the 66th largest by planned enrollment, is one of 11 that started in 2025, is one of 34 with no phase, reaches primary completion later than 5 of the 20 other live ones, and was the 88th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →18 of the 97 studies testing morphine in Pain, Postoperative are open now, in 11 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 21–60
Sohag University · Sites in Egypt
Ages 18–60
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Anne Juul Wikkelsø · Sites in Denmark
Ages 18+ · Women only
Meri Mirceta · Sites in Croatia
Ages 18–80
By country, each count listing its studies:
Morphine: first FDA approval 1984 (DURAMORPH PF). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 11 · Phase 4 42
First in 2001; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 97 interventional studies. Of the 60 that completed or were terminated, 14 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 97 have an industry lead sponsor. The 10 most frequent:
Ataturk University is the lead sponsor of 463 studies on the registry; 123 are open to participants now.
34 studies in Pain, Postoperative by Ataturk University: 10 open now, 11 under way, none of them phase 3. Of 21 finished, 0 (0%) have results posted.
Among the 34 studies in Pain, Postoperative by Ataturk University, this one is the 18th largest by planned enrollment, is one of 7 that started in 2025, is one of 33 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 25th registered.
Ataturk University’s Pain, Postoperative studies by the year they started, since 2016.
5 of the studies testing morphine in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07720739Sohag UniversityEfficacy of Adding Intrathecal Morphine to Erector Spinae Plane Block for Postoperative Analgesia After Midline Laparotomy | 2026-11 |
| NCT06761989Seoul National University HospitalIntrathecal Morphine Injection Versus Continuous Wound Infiltration After Pancreaticoduodenectomy | 2026-12-31 |
| NCT06797973Anne Juul WikkelsøEfficacy and Safety of Intrathecal Morphine for Postoperative Pain Management Following Planned Caesarean Section | 2027-05-31 |
| NCT05351229Northwestern UniversityIntrathecal Morphine for Analgesia in Video-assisted and Robotic-assisted Thoracic Surgery | 2027-06-01 |
| NCT07803133Erzincan Binali Yildirim UniversitesiPENG Block Versus Intrathecal Morphine for Early Postoperative Recovery After Total Hip Arthroplasty | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 97 studies testing morphine in Pain, Postoperative, from their registry updates:
Among Ataturk University’s 34 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
This study aims to compare the effects of intrathecal morphine with trocar-site infiltration and intraperitoneal bupivacaine on postoperative pain control, quality of recovery, and inflammatory response in patients undergoing elective laparoscopic hysterectomy. Laparoscopic hysterectomy is widely used for benign gynecologic conditions, but postoperative pain may result from trocar-site trauma, peritoneal irritation, and carbon dioxide insufflation. Effective postoperative analgesia can improve patient comfort, reduce opioid use, and enhance early recovery.
Intrathecal morphine is known to provide potent early postoperative analgesia but may cause side effects such as nausea, vomiting, pruritus, and respiratory depression. Local anesthetic techniques, including trocar-site infiltration and intraperitoneal bupivacaine, have also been shown to reduce postoperative pain after minimally invasive gynecologic surgery.
In this prospective, randomized, double-blind study, patients will be assigned to one of two groups:
Intrathecal morphine (ITM) administered before induction of anesthesia;
Local anesthesia group (LA) receiving trocar-site infiltration and intraperitoneal bupivacaine at the end of surgery.
The primary outcome is the Quality of Recovery-15 (QoR-15) score at 24 hours. Secondary outcomes include pain scores, opioid consumption, time to first rescue analgesia, postoperative nausea and vomiting, pruritus, respiratory depression, early mobilization, bowel function recovery, and perioperative inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII).
The results of this trial are expected to guide clinicians in selecting optimal analgesic strategies for laparoscopic hysterectomy and to contribute to improved patient recovery and postoperative satisfaction.
Study Background and Rationale:
Despite its minimally invasive advantages, laparoscopic hysterectomy can cause significant postoperative pain due to trocar sites, visceral manipulation, and peritoneal irritation. This pain results in opioid consumption, associated side effects, and delayed recovery. Multimodal analgesia is the cornerstone of postoperative care. In this context, trocar site infiltration with intrathecal morphine (long-acting central analgesia) and intraperitoneal local anesthetic administration (peripheral techniques targeting somatic and visceral pain) are effective options. This study aims to compare the effects of these two different analgesic strategies on the quality of postoperative recovery through a patient-centered outcome measure, the QoR-15, and objective hematologic inflammatory markers.
Technical Details of Intervention Protocols:
General Anesthesia Standardization: All patients will receive standard general anesthesia. Induction will be achieved with propofol and fentanyl, rocuronium bromide will be used for neuromuscular blockade, and anesthesia will be maintained with sevoflurane.
Group ITM (Intrathecal Morphine) Intervention: Before induction of general anesthesia, patients will be in the sitting or lateral decubitus position and 200 µg (0.2 mg) of morphine will be injected into the subarachnoid space with a 25G (or 27G) pencil-point spinal needle at the L3-L4 intervertebral space. Hemodynamic and respiratory parameters will be closely monitored for 30 minutes after the injection.
Group LA (Local Anesthetic) Intervention: At the end of the surgical procedure, 5 mL of 0.25% bupivacaine will be infiltrated into each trocar incision. Additionally, 40 mL of 0.25% bupivacaine will be administered intraperitoneally, distributing to the subhepatic, diaphragmatic, and pelvic surfaces. The total bupivacaine dose will be calculated to avoid exceeding 2 mg/kg body weight to avoid the risk of toxicity.
Standard Perioperative Medication Regimen: All patients in both groups will receive the following medications intraoperatively as part of multimodal analgesia: 1 g Paracetamol, 800 mg Ibuprofen, 3 mg Granisetron, 40 mg Esomeprazole, and 8 mg Dexamethasone.
Methodological Details for Outcome Assessments:
QoR-15 Questionnaire: The validated and reliable Turkish version of the primary outcome measure, QoR-15, will be used. The questionnaire will be administered before surgery to obtain preoperative baseline values and at 24 hours postoperatively as the primary outcome.
Pain and Side Effect Monitoring: Postoperative pain will be assessed using a Visual Analog Scale (VAS: 0-10 cm) at rest and during coughing/activity. Assessments will be made at 2-hour intervals from the 2nd postoperative hour to the 24th hour. Nausea, vomiting, pruritus, and respiratory depression (SpO2 \< 90% or respiratory rate \< 8/minute) will be recorded using standard forms.
Hematological Inflammatory Markers: A complete blood count will be analyzed using an automated hematology analyzer from venous blood samples taken preoperatively (baseline, T0) and at the 24th postoperative hour (T13). Neutrophil/Lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR), Lymphocyte/Monocyte Ratio (LMR), and Systemic Immuno-Inflammation Index (SII = (Platelet count x Neutrophil count) / Lymphocyte count) will be calculated.
Blinding Protocol: Except for the anesthesiologist who performs the randomization and intervention, the patients, the surgical team, the investigators collecting postoperative data, and the statistical analyst will be blinded to group distinctions. Randomization will be stored using sequential, numbered, opaque envelopes.
Clinical Significance of the Study:
The findings of this study may provide evidence-based recommendations regarding the most effective multimodal analgesia regimen after laparoscopic hysterectomy. The demonstrated superiority of intrathecal morphine in reducing the systemic inflammatory response and patient-reported quality of recovery may result in less opioid use and faster recovery. Conversely, if local anesthetic techniques are adequate, the potential risks of central block may be avoided.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive 200 µg of preservative-free intrathecal morphine administered at the L3-L4 interspace prior to induction of general anesthesia. This intervention is intended to provide early postoperative analgesia following laparoscopic hysterectomy.
Drug: Intrathecal Morphine
Participants in this arm will receive 0.25% bupivacaine infiltration (5 mL at each trocar site) and 40 mL of 0.25% bupivacaine administered intraperitoneally at the end of surgery. The total dose of bupivacaine will not exceed 2 mg/kg. This technique aims to reduce postoperative somatic and visceral pain after laparoscopic hysterectomy.
Drug: Trocar-Site Bupivacaine Infiltration · Drug: Intraperitoneal Bupivacaine spray
A single dose of 200 µg preservative-free morphine will be administered intrathecally at the L3-L4 interspace prior to induction of general anesthesia. The injection is performed using a 25G spinal needle. This intervention aims to provide prolonged early postoperative analgesia in patients undergoing laparoscopic hysterectomy.
At the end of laparoscopic hysterectomy, 5 mL of 0.25% bupivacaine will be infiltrated into each trocar site. This intervention targets somatic pain originating from trocar entry points. It is administered only in the Local Anesthesia (LA) Group. The total dose of bupivacaine from all applications will remain within recommended safety limits.
A total of 40 mL of 0.25% bupivacaine will be instilled intraperitoneally after completion of the surgical procedure. This intervention is designed to reduce visceral and peritoneal irritation-related pain following laparoscopic hysterectomy. The combined bupivacaine dose from trocar-site infiltration and intraperitoneal instillation will not exceed 2 mg/kg.
Postoperative quality of recovery at 24 hours measured by QoR-15
The primary outcome is the overall postoperative recovery quality at 24 hours, assessed using the 15-item Quality of Recovery questionnaire (QoR-15). This scale evaluates physical comfort, emotional state, physical independence, psychological support, and pain to provide a comprehensive patient-centered measure of recovery.
Time frame: 24 hours postoperatively
Time to first rescue opioid requirement
Duration (in hours) from the end of surgery to the first administration of rescue opioid (oxycodone 5 mg) for postoperative pain relief.
Time frame: From end of surgery until first rescue opioid administration (up to 24 hours)
Total opioid consumption within 24 hours
Total amount of rescue opioid consumed by the patient within the first 24 hours after surgery, expressed in milligrams.
Time frame: 0-24 hours postoperatively
Time to first mobilization
Time (in hours) from the end of surgery until the patient is able to ambulate independently for the first time postoperatively.
Time frame: 0-24 hours postoperatively
Time to first bowel movement
Time (in hours) from the end of surgery until the patient reports the first postoperative bowel movement.
Time frame: 0-24 hours postoperatively
Postoperative pain scores (VAS)
Pain intensity will be assessed using the Visual Analog Scale (VAS), a continuous scale ranging from 0 to 10. Scores are recorded by patients marking a line, where 0 represents "no pain" and 10 represents "the worst pain imaginable". Higher scores indicate a worse outcome (more severe pain). Assessments will be performed at rest and during movement (e.g., coughing) at 2-hour intervals from 2 to 24 hours postoperatively.
Time frame: 2-24 hours postoperatively
Postoperative complications
Incidence of postoperative nausea, vomiting, pruritus, and respiratory depression within the first 24 hours after surgery.
Time frame: 0-24 hours postoperatively
Neutrophil-to-lymphocyte ratio (NLR)
NLR measured preoperatively and at 24 hours postoperatively to evaluate systemic inflammatory response.
Time frame: Preoperative baseline and 24 hours postoperatively
Platelet-to-lymphocyte ratio (PLR)
PLR measured preoperatively and at 24 hours postoperatively to evaluate systemic inflammatory response.
Time frame: Preoperative baseline and 24 hours postoperatively
Lymphocyte-to-monocyte ratio (LMR)
LMR measured preoperatively and at 24 hours postoperatively to evaluate systemic inflammatory response.
Time frame: Preoperative baseline and 24 hours postoperatively
Systemic immune-inflammation index (SII)
SII measured preoperatively (T0) and at 24 hours postoperatively (T13) to evaluate systemic inflammatory response.
Time frame: Preoperative baseline and 24 hours postoperatively
Plan to share: No — Individual participant data (IPD) will not be shared because the study involves sensitive patient health information, and data confidentiality will be strictly maintained according to institutional ethical guidelines.
Started Dec 2025 (actual). Primary completion is estimated for Jun 2026, 6 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 6 months is below that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Morphine